Form 4: Enanta Pharma Officer Sells Shares for Tax Cover

Enanta Pharmaceuticals' Chief Product Strategy Officer, Tara Lynn Kieffer, sold 2,106 shares of common stock to cover tax withholding obligations related to a restricted stock unit award.

Summary

• Tara Lynn Kieffer, Chief Product Strategy Officer of Enanta Pharmaceuticals Inc. (ENTA), reported a transaction on December 5, 2025.
• The transaction involved the sale of 2,106 shares of Common Stock.
• The shares were sold at a weighted-average price of $14.23 per share, with individual sales ranging from $13.89 to $14.46.
• This sale was explicitly stated as a 'sell to cover' transaction to satisfy tax withholding obligations resulting from the settlement of a restricted stock unit (RSU) award granted on November 23, 2022.
• The transaction does not represent a discretionary sale by the reporting person.
• Following this transaction, Tara Lynn Kieffer beneficially owns 30,620 shares of Common Stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a non-discretionary 'sell to cover' for tax purposes, which is a routine event for executives receiving equity compensation and does not reflect a change in management's outlook or confidence in the company.

Industry Context

This filing reports a routine insider transaction for tax purposes and does not provide information relevant to broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary tax-related sale by an officer, not indicative of a change in company fundamentals or management's view on the stock.

Key Dates

Recommendation

The transaction reported is a non-discretionary 'sell to cover' to satisfy tax withholding obligations related to a restricted stock unit award. Such routine transactions by insiders are generally not indicative of their sentiment towards the company's future prospects or a change in fundamental value. Therefore, this filing alone does not warrant a change in investment recommendation, and a 'hold' stance is maintained based on this specific information.

Keywords

Enanta Pharmaceuticals, ENTA, Form 4, Insider Transaction, Stock Sale, Restricted Stock Units, RSU, Tax Withholding, Officer